fbpx

Check out the latest episodes of our Life Science and Food Industry Podcasts. Available everywhere!

X

FDA Approves Bristol Myers’ Cardiac Drug for HCM + New Ovarian Cancer Blood Test – Xtalks Life Science Podcast Ep. 60

FDA Approves Bristol Myers’ Cardiac Drug for HCM + New Ovarian Cancer Blood Test – Xtalks Life Science Podcast Ep. 60

In this episode, Ayesha discussed Bristol Myers Squibb’s new heart drug Camzyos (mavacamten), which has received approval from the US Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). The drug is the first to target the pathophysiology of obstructive HCM and may be Bristol Myers’ next blockbuster cardiac drug. Hear more about the company’s looming patent cliff for some of its drugs as well as the company’s risk evaluation program for Camzyos given some of its safety concerns.

Ayesha also talked about a new ovarian cancer blood test developed by researchers at the University of Manchester that may help diagnose the disease quicker and more accurately, especially in younger women. The test includes a newer ovarian cancer biomarker that when used in combination with CA-125, the biomarker currently used to monitor and screen for ovarian cancer in some cases, could improve its diagnostic value. Learn more about the test and about the importance of women’s health advocacy in the early detection of diseases like ovarian cancer.

The episode marked World Ovarian Cancer Day and was sponsored by Elligo Health Research.

Listen on Apple Podcasts

Read the full articles here:

Researchers Use Emerging Ovarian Cancer Biomarker to Develop New Blood Test for Ovarian Cancer

Camzyos Secures FDA Approval for Obstructive HCM, Bristol Myers Eyes it as its Next Big Cardiac Drug

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.